List of Naropin drug patents

Naropin is owned by Fresenius Kabi Usa.

Naropin contains Ropivacaine Hydrochloride.

Naropin has a total of 4 drug patents out of which 1 drug patent has expired.

Expired drug patents of Naropin are:

  • US8118802

Naropin was authorised for market use on 24 September, 1996.

Naropin is available in solution;injection dosage forms.

The generics of Naropin are possible to be released after 28 November, 2026.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8118802 FRESENIUS KABI USA Connector for packaging containing medical fluids and packaging for medical fluids
May, 2023

(16 days ago)

US8162915 FRESENIUS KABI USA Connector for packings containing medical liquids, and corresponding packing for medical liquids
May, 2024

(11 months from now)

US7828787 FRESENIUS KABI USA Connector for packaging containing medical fluids and packaging for medical fluids
Oct, 2025

(2 years from now)

US7857802 FRESENIUS KABI USA Connector for medical liquid-containing packages and medical liquid-containing packages
Nov, 2026

(3 years from now)

Do you want to check out NAROPIN patents from before 2022?

Drugs and Companies using ROPIVACAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 September, 1996

Treatment: NA

Dosage: SOLUTION;INJECTION

How can I launch a generic of NAROPIN before it's patent expiration?
More Information on Dosage

NAROPIN family patents

9

European Union

5

Germany

4

United States

3

Australia

3

Korea, Republic of

3

Canada

3

Denmark

3

Spain

3

Portugal

3

Poland

3

Japan

3

Norway

3

Hong Kong

3

Slovenia

3

Mexico

3

Brazil

3

China

3

South Africa

2

Austria

1

India

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic